Shots:

• Jacobio highlighted the data from the P-II registrational trial evaluating glecirasib (KRAS G12C inhibitor) alone for NSCLC at the April ASCO Plenary Series
• The data in 2L NSCLC patients depicted a cORR of 47.9% (56/117) incl. CR attained in 4 patients & tumor reduction exceeding 50% (36/117), DCR of 86.3%, mPFS of 8.2mos., mOS of 13.6mos. & DoR of 73.6% (6mos.) & 56.6% (12mos.) with mDoR not attained. 5% patients discontinued due to TRAEs
• Additionally, multiple P-I/II trials of glecirasib are underway across China, the US & the EU for KRAS G12C mutated solid tumors incl. NSCLC study in China, a monotx. study for STK11 co-mutated NSCLC in the frontline setting & combination studies with JAB-3312 for NSCLC & cetuximab for CRC

Ref: Jacobio Pharma | Image: Jacobio Pharma

Related News:- Jacobio Pharma’s Glecirasib Receives the NMPA’s Breakthrough Therapy Designation for the Treatment of Pancreatic Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com